All Updates

All Updates

icon
Filter
Management news
Exscientia lays off up to 25% of workforce as part of cost-saving program
AI Drug Discovery
May 21, 2024
This week:
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
AI Drug Discovery

AI Drug Discovery

May 21, 2024

Exscientia lays off up to 25% of workforce as part of cost-saving program

Management news

  • UK-based Exscientia AI drug discovery firm Exscientia has announced plans to lay off about 20% to 25% of its workforce across various departments as part of a cost-cutting initiative, citing the intention to reduce operating expenses.

  • Through the layoffs, the company expects to incur severance and termination costs between USD 7.4 and USD 9.6 million but will save USD ~40 million annually.

  • The company expects to conclude several multi-year investments this year, including projects related to its proprietary technology platform, leading to the restructuring decisions. Following the changes in October 2023, its ongoing pipeline programs will continue, prioritizing its CDK7 asset, GTAEXS617, and LSD1 inhibitor, EXS74539, and partnering or out-licensing several other programs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.